GlassScriptPhysician profile
Augustus G Stern
NPI 1245405240
$6,078.42
in general payments reported to CMS, 2019-2025
29 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $391 · 2021: $717 · 2022: $463 · 2023: $1,398 · 2024: $1,202 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,569.90 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $619.89 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Sun Pharmaceutical Industries INC. | $607.98 | 2019-2025 | Cequa, Xelpros |
| New World Medical,INC. | $541.67 | 2023-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Glaukos Corporation | $393.06 | 2023-2025 | Idosetr, Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $285.09 | 2019-2022 | |
| Rxsight INC | $263.24 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sight Sciences, INC. | $209.73 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $198.10 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $166.74 | 2024-2025 | Vevye, Iheezo |
| Mallinckrodt Hospital Products INC. | $129.16 | 2021-2023 | Acthar |
| Carl Zeiss Meditec USA, INC. | $105.94 | 2025 | Cirrus Hd-Oct |
| Oyster Point Pharma, INC. | $103.08 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.24 | 2019-2021 | |
| Horizon Therapeutics Plc | $93.08 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $89.91 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $87.84 | 2019-2021 | |
| Omeros Corporation | $77.67 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $77.60 | 2019-2021 | |
| Ocular Therapeutix, INC. | $70.02 | 2024-2025 | Dextenza |
| Dompe US, INC. | $50.05 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $45.36 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $41.57 | 2021-2025 | Tecnis Iol, Tecnis Simplicity |
| Rayner Intraocular Lenses Limited | $40.66 | 2023 | Rayone Spheric, Rayone Aspheric, Omidria |
| Ani Pharmaceuticals, INC. | $26.21 | 2025 | Iluvien |
| Amgen INC. | $25.68 | 2025 | Tepezza |
| Shire North American Group INC | $21.39 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $17.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustus Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.